Medtronic’s Hugo robot claims long-awaited FDA general surgery clearance

Medtronic’s Hugo has claimed a long-awaited general surgery clearance from the FDA, extending the robot’s reach into procedures across the abdomen.

That includes gallbladder removals, small bowel resections and certain gastric bypasses and hernia repairs, as well as appendectomies. Medtronic (NYSE: MDT) estimates these account for about 3.5 million surgeries performed in the U.S. annually, or more than half of all soft-tissue procedures in the country.

The sweeping 510(k) green light comes less than a year after Hugo’s initial December 2025 clearance in urology, covering the removals of prostate, kidney and bladder tissue, including cancers. A separate application to add gynecologic surgery indications remains under agency review. The modular, cart-based system previously picked up a CE mark for general surgery in Europe in 2022.

Sign up for Blog Updates